NCT07139899 Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma
| NCT ID | NCT07139899 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bastiaan Driehuys |
| Condition | Severe Asthma |
| Study Type | OBSERVATIONAL |
| Enrollment | 5 participants |
| Start Date | 2025-11-17 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5 participants in total. It began in 2025-11-17 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with severe asthma. Mucus plugs will be identified using CT imaging, and xenon MRI will be used to evaluate ventilation and gas exchange impairments in regions of the lungs corresponding to the airways downstream of mucus plugs.
Eligibility Criteria
Inclusion Criteria: * Adequate completion of informed consent process with written documentation * Patients 18 - 65 years old * Physician diagnosis of asthma for \> 1 year * Able to perform reproducible spirometry according to ATS criteria based on clinical PFTs within previous 30 days of enrollment * All racial/ethnic backgrounds may participate * Blood eosinophil count \> 300 cells/μL * Smoking history \<10 pack years * No smoking history (including vapes, cigar, or marijuana use) in the last 3 months * About to initiate asthma therapy with either dupilumab, tezepelumab, or benralizumab as part of their standard of care Exclusion Criteria: * Respiratory tract infection within the 4 weeks prior to Visit 1 * Body mass index (BMI) \> 30 at Visit 1 * One-time doses such as intra-articular injections require a 4-week washout prior to Visit 1 * Asthma-related ER visit within the previous 4 weeks of Visit 1 or at any time while on the study * Significant concomitant medical illness, including (but not limited to) heart disease, cancer, uncontrolled diabetes, other chronic lung diseases (determined by the Investigator.) * Resting O2 saturation \<90% with maximum supplemental O2 delivered by nasal cannula * Positive urine pregnancy test at Visit 1 or at any time while on the study * Participation in an intervention study (including bronchoscopy) or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study * Unable or unlikely to complete study assessments in the opinion of the Investigator * Study intervention poses undue risk to patient in the opinion of the Investigator * Conditions that will prohibit MRI scanning determined by the MRI safety screening.
Contact & Investigator
David Mummy, PhD
PRINCIPAL INVESTIGATOR
Duke University
Frequently Asked Questions
Who can join the NCT07139899 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Severe Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07139899 currently recruiting?
Yes, NCT07139899 is actively recruiting participants. Contact the research team at david.mummy@duke.edu for enrollment information.
Where is the NCT07139899 trial being conducted?
This trial is being conducted at Durham, United States.
Who is sponsoring the NCT07139899 clinical trial?
NCT07139899 is sponsored by Bastiaan Driehuys. The principal investigator is David Mummy, PhD at Duke University. The trial plans to enroll 5 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.